These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 35258165)

  • 21. A low-frequency IL4R locus variant in Japanese patients with intravenous immunoglobulin therapy-unresponsive Kawasaki disease.
    Amano Y; Akazawa Y; Yasuda J; Yoshino K; Kojima K; Kobayashi N; Matsuzaki S; Nagasaki M; Kawai Y; Minegishi N; Ishida N; Motoki N; Hachiya A; Nakazawa Y; Yamamoto M; Koike K; Takeshita T
    Pediatr Rheumatol Online J; 2019 Jul; 17(1):34. PubMed ID: 31269967
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The factors affecting the disease course in Kawasaki disease.
    Arslanoglu Aydin E; Ertugrul I; Bilginer Y; Batu ED; Sonmez HE; Demir S; Arici ZS; Sag E; Alehan D; Ozen S
    Rheumatol Int; 2019 Aug; 39(8):1343-1349. PubMed ID: 31139951
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Higher efficacy of infliximab than immunoglobulin on Kawasaki disease, a meta-analysis.
    Li X; Tang Y; Ding Y; Chen Y; Hou M; Sun L; Qian G; Qin L; Lv H
    Eur J Pharmacol; 2021 May; 899():173985. PubMed ID: 33652059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk Factors of Coronary Artery Aneurysms in Kawasaki Disease with a Low Risk of Intravenous Immunoglobulin Resistance: An Analysis of Post RAISE.
    Iio K; Morikawa Y; Miyata K; Kaneko T; Misawa M; Yamagishi H; Miura M
    J Pediatr; 2022 Jan; 240():158-163.e4. PubMed ID: 34461064
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive Value of Serum Lipid for Intravenous Immunoglobulin Resistance and Coronary Artery Lesion in Kawasaki Disease.
    Shao S; Zhou K; Liu X; Liu L; Wu M; Deng Y; Duan H; Li Y; Hua Y; Wang C
    J Clin Endocrinol Metab; 2021 Sep; 106(10):e4210-e4220. PubMed ID: 33837779
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety associated with the infusion speed of intravenous immunoglobulin for the treatment of Kawasaki disease: a randomized controlled trial.
    Fukui S; Seki M; Minami T; Kotani K; Oka K; Yokomizo A; Matsubara D; Sato T; Nozaki Y; Saito M; Kikuchi Y; Miyamoto K; Monden Y; Yamagata T
    Pediatr Rheumatol Online J; 2021 Jul; 19(1):107. PubMed ID: 34217297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Platelet Count Variation and Risk for Coronary Artery Abnormalities in Kawasaki Disease.
    Ae R; Abrams JY; Maddox RA; Schonberger LB; Nakamura Y; Shindo A; Kuwabara M; Makino N; Matsubara Y; Kosami K; Sasahara T; Belay ED
    Pediatr Infect Dis J; 2020 Mar; 39(3):197-203. PubMed ID: 31851145
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation of Coronary Artery Abnormalities with Fever Pattern in Patients with Kawasaki Disease.
    Tanaka A; Inoue M; Hoshina T; Koga H
    J Pediatr; 2021 Sep; 236():95-100. PubMed ID: 34019881
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of different doses of aspirin on the prognosis of Kawasaki disease.
    Wang J; Chen H; Shi H; Zhang X; Shao Y; Hang B; Xu Z; Rong X; Chu M; Qiu H
    Pediatr Rheumatol Online J; 2020 Jun; 18(1):48. PubMed ID: 32527316
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between P2RY12 Gene Polymorphisms and IVIG Resistance in Kawasaki Patients.
    Wang Z; Xu Y; Zhou H; Wang Y; Li W; Lu Z; Jiang Z; Gu X; Zheng H; Zeng L; Huang P; Zhang L; Gu X
    Cardiovasc Ther; 2020; 2020():3568608. PubMed ID: 32256707
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.
    Uehara R; Belay ED; Maddox RA; Holman RC; Nakamura Y; Yashiro M; Oki I; Ogino H; Schonberger LB; Yanagawa H
    Pediatr Infect Dis J; 2008 Feb; 27(2):155-60. PubMed ID: 18174868
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of FcγRIIA and FcγRIIB on coronary artery lesion formation and intravenous immunoglobulin treatment responses in children with Kawasaki disease.
    Chang LS; Lo MH; Li SC; Yang MY; Hsieh KS; Kuo HC
    Oncotarget; 2017 Jan; 8(2):2044-2052. PubMed ID: 27893416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk factors of immunoglobulin resistance and coronary complications in children with Kawasaki disease.
    Berdej-Szczot E; Małecka-Tendera E; Gawlik T; Firek-Pędras M; Szydłowski L; Gawlik A
    Kardiol Pol; 2017; 75(3):261-266. PubMed ID: 27995598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of early intravenous immunoglobulin therapy for Kawasaki disease: The 22nd nationwide survey in Japan.
    Kuwabara M; Yashiro M; Ae R; Yanagawa H; Nakamura Y
    Int J Cardiol; 2018 Oct; 269():334-338. PubMed ID: 30049499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials.
    Lei WT; Chang LS; Zeng BY; Tu YK; Uehara R; Matsuoka YJ; Su KP; Lee PC; Cavalcante JL; Stubbs B; Lin PY; Wu YC; Hsu CW; Chen TY; Chen YW; Yeh PY; Sun CK; Tseng PT; Kao YH
    EBioMedicine; 2022 Apr; 78():103946. PubMed ID: 35306339
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
    Qiu H; He Y; Rong X; Ren Y; Pan L; Chu M; Wu R; Shi H
    Postgrad Med; 2018 May; 130(4):442-447. PubMed ID: 29745742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical implications of procalcitonin in Kawasaki disease: a useful candidate for differentiating from sepsis and evaluating IVIG responsiveness.
    Niu MM; Jiang Q; Ruan JW; Liu HH; Chen WX; Qiu Z; Fan GZ; Li RX; Wei W; Hu P
    Clin Exp Med; 2021 Nov; 21(4):633-643. PubMed ID: 33839960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk stratification in the decision to include prednisolone with intravenous immunoglobulin in primary therapy of Kawasaki disease.
    Kobayashi T; Inoue Y; Otani T; Morikawa A; Kobayashi T; Takeuchi K; Saji T; Sonobe T; Ogawa S; Miura M; Arakawa H
    Pediatr Infect Dis J; 2009 Jun; 28(6):498-502. PubMed ID: 19504733
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk Factors of Coronary Artery Abnormalities and Resistance to Intravenous Immunoglobulin Plus Corticosteroid Therapy in Severe Kawasaki Disease: An Analysis of Post RAISE.
    Miyata K; Miura M; Kaneko T; Morikawa Y; Sakakibara H; Matsushima T; Misawa M; Takahashi T; Nakazawa M; Tsuchihashi T; Yamashita Y; Obonai T; Chiga M; Hori N; Komiyama O; Yamagishi H
    Circ Cardiovasc Qual Outcomes; 2021 Feb; 14(2):e007191. PubMed ID: 33541111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of intravenous immunoglobulin resistance and coronary artery aneurysm in patients with Kawasaki disease.
    Chantasiriwan N; Silvilairat S; Makonkawkeyoon K; Pongprot Y; Sittiwangkul R
    Paediatr Int Child Health; 2018 Aug; 38(3):209-212. PubMed ID: 29768976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.